CERVICAL CARCINOMA

1. **Specimen(s):** list all specimens removed during case

2. **Procedure(s):** select all that apply
   a. [Loop electrical excision procedure (LEEP)]
   b. [Large loop excision of the transformation zone (LLETZ)]
   c. [Cold knife cone excision]
   d. [Trachelectomy]
   e. [Total abdominal hysterectomy]
   f. [Radical hysterectomy]
   g. [Pelvic exenteration]
   a. [Bilateral salpingo-oophorectomy]
   b. [Bilateral oophorectomy]
   c. [Bilateral salpingectomy]
   d. [Right salpingo-oophorectomy]
   e. [Right oophorectomy]
   f. [Right salpingectomy]
   g. [Left salpingo-oophorectomy]
   h. [Left oophorectomy]
   i. [Left salpingectomy]
   j. [Omentectomy]
   k. [Peritoneal biopsies]
   l. [Peritoneal washings]
   h. [Other, <SPECIFY>]

3. **Sentinel Lymph Node Sampling:** select whether or not sentinel lymph nodes were removed
   a. [Performed]
   b. [Not performed]
   c. [Not applicable]
   d. [Cannot be determined]

4. **Regional Lymph Node Sampling:** select whether or not regional lymph nodes were removed
   a. [Performed]
   b. [Not performed]
   c. [Not applicable]
   d. [Cannot be determined]

5. **Specimen Integrity:** document whether intact or received fragmented. This absolutely requires correlating with the operative report.

6. **Primary Tumor Site:** select all that apply
   a. [Left superior quadrant (12 to 3 o’clock)]
   b. [Left inferior quadrant (3 to 6 o’clock)]
c. [Right inferior quadrant (6 to 9 o’clock)]

d. [Right superior quadrant (9 to 12 o’clock)]

e. [Multicentric, \(<\text{SPECIFY}>\)]

f. [Circumferential]

g. [Other, \(<\text{SPECIFY}>\)]

h. [Cannot be determined]

7. **Tumor Size:** *provide greatest dimension and total dimensions*

   a. [Greatest dimension: \(<\text{PROVIDE GREATEST DIMENSION}>\)]

   b. [Total dimensions: \(<\text{PROVIDE ADDITIONAL}>\)]

   c. [Cannot be determined]

8. **Histologic Type:** *select appropriate tumor type*

   a. [Squamous cell carcinoma, keratinizing type]

   b. [Squamous cell carcinoma, non-keratinizing type]

   c. [Squamous cell carcinoma, basaloid type]

   d. [Squamous cell carcinoma, papillary type]

   e. [Squamous cell carcinoma, lymphoepithelioma-like]

   f. [Verrucous carcinoma]

   g. [Adenocarcinoma, usual type (HPV-related)]

   h. [Adenocarcinoma, gastric type (not HPV-related; includes minimal deviation adenocarcinoma)]

   i. [Clear cell carcinoma]

   j. [Serous carcinoma]

   k. [Mesonephric carcinoma]

   l. [Adenosquamous carcinoma]

   m. [Adenoid basal cell carcinoma]

   n. [Adenoid cystic carcinoma]

   o. [Small cell carcinoma]

   p. [Neuroendocrine carcinoma, low-grade]

   q. [Neuroendocrine carcinoma, high-grade]

   r. [Undifferentiated carcinoma]

   s. [Carcinosarcoma (malignant mixed Mullerian tumor, MMT)]

   t. [Carcinoma, not-otherwise-specified]

   u. [Other, \(<\text{SPECIFY}>\)]

9. **Histologic Grade:** *specify histologic grade of tumor*

   a. If squamous carcinoma, usual-type adenocarcinoma, gastric-type mucinous adenocarcinoma, mesonephric adenocarcinoma, adenosquamous carcinoma, use WHO three-tiered system:

   i. [Well-differentiated (grade 1)]
ii. [Moderately-differentiated (grade 2)]
iii. [Poorly-differentiated (grade 3)]
iv. [Other, <SPECIFY>]
b. If verrucous carcinoma, then use [well-differentiated (grade 1)]
c. If serous carcinoma, small cell carcinoma, clear cell carcinoma, or carcinosarcoma, then use [high-grade]

10. Stromal Invasion: specify presence of stromal invasion
   a. [Absent]
   b. [Present, <PROVIDE DEPTH OF INVASION>]
      i. [< 33% cervical stromal thickness]
      ii. [≥ 33% to < 66% cervical stromal thickness]
      iii. [≥ 66% cervical stromal thickness]

11. Lymph-Vascular Space Invasion: state whether LVI is present
   a. [Absent]
   b. [Present]
   c. [Suspicious]
   d. [Cannot be determined]

12. Other Sites/Organs Involved: state whether there is disease outside the cervix
   a. [Negative]
   b. [Positive: <LIST OTHER ORGANS INVOLVED> ; <PROVIDE SIZE OF LARGEST METASTATIC FOCUS>]

13. Regional Lymph Node Status: provide total sentinel and non-sentinel lymph node status
   a. It is important to indicate how big the metastasis is because this affects staging.
   b. Sentinel Lymph Nodes:
      i. [Not performed]
      ii. If all lymph nodes are negative: [Negative: 0 / <PROVIDE TOTAL # OF SENTINEL LYMPH NODES>]
      iii. If there are lymph nodes with carcinoma:
         1. [Number of lymph nodes with metastasis greater than 0.02 cm (bigger than ITCs)]
         2. [Number of lymph nodes with isolated tumor cells (ITCs; single cells or small clusters of cells not more than 0.02 cm in greatest dimension)]
         3. [State anatomic site of positive lymph node(s)]
         4. [State presence/absence of extranodal extension]
         5. [Give total number of sentinel lymph nodes]
   c. Non-sentinel Lymph Nodes:
      i. [Not performed]
ii. If all lymph nodes are negative: [Negative: 0 / <PROVIDE TOTAL # OF SENTINEL LYMPH NODES>]

iii. If there are lymph nodes with carcinoma:
   1. [Number of lymph nodes with metastasis greater than 0.02 cm (bigger than ITCs)]
   2. [Number of lymph nodes with isolated tumor cells (ITCs; single cells or small clusters of cells not more than 0.02 cm in greatest dimension)]
   3. [State anatomic site of positive lymph node(s)]
   4. [State presence/absence of extranodal extension]
   5. [Give total number of non-sentinel lymph nodes]

d. Total Lymph Nodes:
   i. [Not performed]
   ii. If all lymph nodes are negative: [Negative: 0 / <PROVIDE TOTAL LYMPH NODES>]
   iii. If there are lymph nodes with carcinoma:
      1. [Number of lymph nodes with metastasis greater than 0.02 cm (bigger than ITCs)]
      2. [Number of lymph nodes with isolated tumor cells (ITCs; single cells or small clusters of cells not more than 0.02 cm in greatest dimension)]
      3. [State anatomic site of positive lymph node(s)]
      4. [State presence/absence of extranodal extension]
      5. [Give grand total # of lymph nodes (i.e. sentinel + non-sentinel)]

14. **Cytology:** state whether or not cytology was performed and results, include accession number
   a. [Not performed]
   b. [Performed]:
      i. [Positive, <PROVIDE ACCESSION NUMBER IF AVAILABLE>]
      ii. [Negative, <PROVIDE ACCESSION NUMBER IF AVAILABLE>]

15. **Surgical Margins:** select all that apply
   a. Endocervical margin:
      i. [Endocervical margin: Negative for invasive and in-situ carcinoma]
      ii. [Endocervical margin: Positive for invasive carcinoma; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]]
      iii. [Endocervical margin: Positive for in-situ carcinoma only; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]]
   b. Ectocervical margin:
      i. [Ectocervical margin: Negative for invasive and in-situ carcinoma]
      ii. [Ectocervical margin: Positive for invasive carcinoma; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]]
iii. [Ectocervical margin: Positive for in-situ carcinoma only; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]]

c. Deep margin:
   i. [Deep margin: Negative for invasive and in-situ carcinoma]
   ii. [Deep margin: Positive for invasive carcinoma; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]]
   iii. [Deep margin: Positive for in-situ carcinoma only; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]]

d. Other margins: (including parametrial soft tissue margins)
   i. [Negative for invasive and in-situ carcinoma]
   ii. [Positive for invasive carcinoma; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]]
   iii. [Positive for in-situ carcinoma only; [Focal] OR [Diffuse, <PROVIDE APPROXIMATE LINEAR EXTENT>]]

16. **Pathologic Staging:** *use AJCC and/or FIGO; refer to staging manuals*